Free Trial
NASDAQ:ALT

Altimmune (ALT) Stock Price, News & Analysis

Altimmune logo
$5.92 +0.72 (+13.85%)
Closing price 04:00 PM Eastern
Extended Trading
$5.95 +0.03 (+0.51%)
As of 05:27 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Altimmune Stock (NASDAQ:ALT)

Key Stats

Today's Range
$5.36
$6.05
50-Day Range
$5.20
$7.45
52-Week Range
$5.14
$11.16
Volume
12.13 million shs
Average Volume
3.05 million shs
Market Capitalization
$455.92 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$20.83
Consensus Rating
Moderate Buy

Company Overview

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.

Remove Ads

Altimmune Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
55th Percentile Overall Score

ALT MarketRank™: 

Altimmune scored higher than 55% of companies evaluated by MarketBeat, and ranked 568th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Altimmune has received a consensus rating of Moderate Buy. The company's average rating score is 2.89, and is based on 6 buy ratings, 2 hold ratings, and no sell ratings.

  • Amount of Analyst Coverage

    Altimmune has only been the subject of 3 research reports in the past 90 days.

  • Read more about Altimmune's stock forecast and price target.
  • Earnings Growth

    Earnings for Altimmune are expected to grow in the coming year, from ($1.35) to ($0.96) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Altimmune is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Altimmune is -3.82, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Altimmune has a P/B Ratio of 2.15. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

  • Read more about Altimmune's valuation and earnings.
  • Percentage of Shares Shorted

    31.77% of the float of Altimmune has been sold short.
  • Short Interest Ratio / Days to Cover

    Altimmune has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Altimmune has recently decreased by 3.56%, indicating that investor sentiment is improving.
  • Dividend Yield

    Altimmune does not currently pay a dividend.

  • Dividend Growth

    Altimmune does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    31.77% of the float of Altimmune has been sold short.
  • Short Interest Ratio / Days to Cover

    Altimmune has a short interest ratio ("days to cover") of 8.2.
  • Change versus previous month

    Short interest in Altimmune has recently decreased by 3.56%, indicating that investor sentiment is improving.
  • News Sentiment

    Altimmune has a news sentiment score of 0.06. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.72 average news sentiment score of Medical companies.
  • News Coverage This Week

    MarketBeat has tracked 9 news articles for Altimmune this week, compared to 8 articles on an average week.
  • Search Interest

    34 people have searched for ALT on MarketBeat in the last 30 days. This is an increase of 89% compared to the previous 30 days.
  • MarketBeat Follows

    Only 6 people have added Altimmune to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Altimmune insiders have bought more of their company's stock than they have sold. Specifically, they have bought $52,000.00 in company stock and sold $0.00 in company stock.

  • Percentage Held by Insiders

    Only 4.10% of the stock of Altimmune is held by insiders.

  • Percentage Held by Institutions

    78.05% of the stock of Altimmune is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

  • Read more about Altimmune's insider trading history.
Receive ALT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Altimmune and its competitors with MarketBeat's FREE daily newsletter.

ALT Stock News Headlines

Stifel Nicolaus Keeps Their Buy Rating on Altimmune (ALT)
Evercore bullish on Altimmune, likes drug move into alcohol related disease
Lying in hospital… staring at the light
"Please don’t die on me," the nurse begged as Porter Stansberry lay in a hospital bed, his heart stopped from years of pushing himself too hard. At his lowest point, he realized that everything had gone wrong, and he was forced to rebuild—not just his health, but his entire life and fortune. After clawing his way out of that abyss, Porter discovered a life-changing investment strategy, one that allowed him to rebuild his wealth far faster and with less risk than he ever imagined. This approach helped him earn enormous returns outside of the volatile stock market, and now he’s sharing it with you. While most won’t believe it’s possible, Porter is asking you to open your mind and consider a new way of investing—one that could transform your financial future, just as it did for him.
Piper Sandler Reaffirms Their Buy Rating on Altimmune (ALT)
Altimmune (ALT) Gets a Hold from William Blair
HC Wainwright Estimates Altimmune's Q2 Earnings (NASDAQ:ALT)
Altimmune to Host Virtual R&D Day on March 13, 2025
See More Headlines

ALT Stock Analysis - Frequently Asked Questions

Altimmune's stock was trading at $7.21 at the beginning of the year. Since then, ALT stock has decreased by 17.9% and is now trading at $5.92.
View the best growth stocks for 2025 here
.

Altimmune, Inc. (NASDAQ:ALT) issued its earnings results on Thursday, February, 27th. The company reported ($0.33) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.34) by $0.01. The business had revenue of $0.01 million for the quarter, compared to analysts' expectations of $0 million. Altimmune had a negative trailing twelve-month return on equity of 55.81% and a negative net margin of 199,076.92%.

Altimmune's stock reverse split before market open on Friday, September 14th 2018. The 1-30 reverse split was announced on Thursday, September 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, September 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 3 shares after the split.

Altimmune's top institutional investors include Ameriprise Financial Inc. (7.39%), Vanguard Group Inc. (6.23%), Geode Capital Management LLC (2.33%) and Bellevue Group AG (1.33%). Insiders that own company stock include Vipin K Garg, David Drutz, Matthew Scott Harris, Wayne Pisano, M Scot Roberts and Diane Jorkasky.
View institutional ownership trends
.

Shares of ALT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Altimmune investors own include Invesco QQQ (QQQ), Meta Platforms (META), NVIDIA (NVDA), Advanced Micro Devices (AMD), Tesla (TSLA), Pfizer (PFE) and SPDR S&P 500 ETF Trust (SPY).

Company Calendar

Last Earnings
2/27/2025
Today
3/14/2025
Next Earnings (Estimated)
5/08/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Pharmaceutical preparations
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:ALT
Employees
50
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$20.83
High Stock Price Target
$26.00
Low Stock Price Target
$12.00
Potential Upside/Downside
+255.8%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.89
Research Coverage
9 Analysts

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-88,450,000.00
Net Margins
-199,076.92%
Pretax Margin
-199,076.92%

Debt

Sales & Book Value

Annual Sales
$20,000.00
Price / Sales
22,545.85
Price / Cash Flow
N/A
Book Value
$2.75 per share
Price / Book
2.13

Miscellaneous

Free Float
68,209,000
Market Cap
$450.92 million
Optionable
Optionable
Beta
0.87
2025 Gold Forecast: A Perfect Storm for Demand Cover

Unlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.

Get This Free Report

This page (NASDAQ:ALT) was last updated on 3/14/2025 by MarketBeat.com Staff
From Our Partners